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ABSTRACT
Norowski, Peter Andrew. Ph.D. The University of Memphis. December 2011. In
Vitro Evaluation of Electrospun Chitosan Mats Crosslinked with Genipin as Guided
Tissue Regeneration Barrier Membranes. Major Professor: Joel D. Bumgardner Ph.D.
Guided tissue regeneration (GTR) is a surgical technique commonly used to
exclude bacteria and soft tissues from bone graft sites in oral/maxillofacial bone graft
sites by using a barrier membrane to maintain the graft contour and space. Current
clinical barrier membrane materials based on expanded polytetrafluoroethylene (ePTFE)
and bovine type 1 collagen are non-ideal and experience a number of disadvantages
including membrane exposure, bacterial colonization/biofilm formation and premature
degradation, all of which result in increased surgical intervention and poor bone
regeneration. These materials do not actively participate in tissue regeneration, however
bioactive materials, such as chitosan, may provide advantages such as the ability to
stimulate wound healing and de novo bone formation. Our hypothesis is that electrospun
chitosan GTR membranes will support cell attachment and growth but prevent cell
infiltration/penetration of membrane, demonstrate in vitro degradation predictive of 4-6
month in vivo functionality, and will deliver antibiotics locally to prevent/inhibit
periopathogenic complications. To test this hypothesis a series of chitosan membranes
were electrospun, in the presence or absence of genipin, a natural crosslinking agent, at
concentrations of 5 and 10 mM. These membranes were characterized by scanning
electron microscopy, tensile testing, suture pullout testing, Fourier transform infrared
spectroscopy, X-ray diffraction, and gel permeation chromatography, and in vitro
biodegradation for diameter/morphology of fibers, membrane strengths, degree of
crosslinking, crystallinity, molecular weight, and degradation kinetics, respectively.
Cytocompability of membranes was evaluated in osteoblastic, fibroblastic and monocyte
iv

cultures. The activity of minocycline loaded and released from the membranes was
determined in zone of inhibition tests using P. gingivalis microbe. The results
demonstrated that genipin crosslinking extended the in vitro degradation timeframe,
extended the release of minocycline, and increased the tensile strength of the resultant
membranes while cytocompatibility, swelling, and tear strength were unaffected. In
conclusion, electrospun chitosan membranes crosslinked with genipin are a suitable
material for guided tissue regeneration and may help reduce bacterial infection and
bacteria-induced host inflammatory response.
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PREFACE

The main body of the work presented in this dissertation is aimed at
characterizing and evaluating the potential of genipin-crosslinked electrospun chitosan
membranes to act as guided tissue regeneration membranes. The work was been
organized and submitted to or prepared for submission to three peer-reviewed journals for
publication. Chapter 2 is submitted and under consideration for publication in the Journal
of Tissue Engineering and Regenerative Medicine as a manuscript entitled “Novel
naturally crosslinked electrospun nano-fibrous chitosan mats for guided bone
regeneration membranes: material characterization and cytocompatibility.” Chapter 3 is
prepared for submission to the Journal of Biomedical Materials Research - Part A in a
manuscript entitled “Suture pullout strength and in vitro fibroblast and RAW 264.7
monocyte biocompatibility of genipin crosslinked nano-fibrous chitosan mats for guided
tissue regeneration.” Chapter 4 of this dissertation will be submitted for publication in
the Journal of Journal of Antimicrobial Chemotherapy as a manuscript entitled
“Antimicrobial activity of minocycline-loaded genipin-crosslinked electrospun chitosan
membranes for guided tissue regeneration.”
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Chapter 1. Introduction
Background
Guided bone regeneration (GBR) and guided tissue regeneration (GTR) are conceptually
similar: the prior is concerned with the formation of bone, and the latter is a wider term
used to describe the guided regeneration of bone and/or associated soft tissues. These
surgical procedures use an implant known as a barrier membrane, to maintain the contour
and space by excluding the faster healing soft tissue from the bone graft space. Barrier
membranes are used in many surgical applications. They are commonly used to maintain
the space of any significantly large bone graft placed in the craniofacial regions, and
along with bleeding bone and graft material help maintain a localized osteogenic
environment [1]. Procedures that may require the use of a barrier membrane include
bone grafts due to bone resection, bone atrophy [2] or trauma [3], socket preservation [1],
orbital floor reconstruction [4], osteotomy and cleft palate repair [5], sinus augmentation
(to repair a perforated sinus membrane) [6], and also compound distal tibial fractures and
other challenging orthopedic reconstructions [7, 8].
However, one of the most heavily researched and challenging applications of
barrier membranes is when they are used to treat intra-bony defects associated with
periodontitis [1, 3, 9-21]. Periodontitis is an inflammatory disease that causes the
destruction of supporting bone and soft tissue around teeth. It is reported that 31% of
people in the United States display mild forms, 13% show moderate severity, and 4%
have advanced disease symptoms [22]. As much as 40-50% of the worldwide adult
population exhibits some form of periodontitis [23]. This inflammatory disease, driven
by gram negative bacteria, termed periopathogens, causes the host-mediated destruction
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of soft tissue and bone eventually leading to the premature loss of the tooth [24]. The
tissue destruction is localized around the supporting tissues of a tooth creating a
periodontal lesion, or an intra-bony defect with a deep gingival pocket where anaerobic
gram-negative bacteria can thrive. There are a variety of periodontal treatment options
that can be undertaken to save a tooth suffering from periodontitis, but for periodontal
pockets deeper than 4.2 mm, surgical treatment is advocated to restore bony height and
clinical attachment [25, 26]. Research has shown that use of GTR barrier membranes to
treat periodontal defects improves clinical parameters, including soft tissue attachment
gain and hard tissue gain, compared to open flap debridement surgery alone [15].
However, the improvements in clinical outcome are widely variable and unpredictable
when using GTR membranes [15]. Even more clinically challenging is restoring bone in
patients who are smokers, diabetics [27], or when the defect is large and deep enough to
involve the furcation of the tooth [18-21]. The mechanism of action of barrier
membranes is thought to be that they exclude the faster healing soft tissues of the gingiva
and support a localized osteogenic environment in the graft space. There are a multitude
of bone graft products which generate bone quite predictably, but the remaining clinical
challenge is regeneration of associated soft tissues of the tooth, specifically the
periodontal ligament and cementum (where the ligament anchors into the root surface).
Clinically-used barrier membrane materials include expanded
polytetrafluoroethylene (ePTFE), degradable synthetic polymers, and bovine type 1
collagen. The consensus is that in terms of bone regeneration capabilities, i.e. the ability
to restore bony height (clinical attachment level), ePTFE membranes are the gold
standard, followed by type 1 collagen membranes, and synthetic polymers are a distant
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third and are not used as often [28-30]. However, many clinicians prefer collagen
membranes to ePTFE because they are easier to handle and do not require a follow-up
membrane-removal surgery, which is time-consuming, costly, and painful to the patient.
Collagen membranes have their own set of drawback including rapid and unpredictable
degradation, and they may not maintain barrier function for the full healing and
regeneration period of 4-6 months [31]. Collagen membranes, crosslinked with
glutaraldehyde, have slower degradation rates, but they also have poor tissue response,
become exposed more often [32] and elicit less bone formation than uncrosslinked
collagen membranes [31]. Additional problems with collagen and ePTFE membranes
include infection, wound dehiscence and membrane exposure [14, 33, 34] and premature
membrane degradation [31] especially when exposed to the oral cavity [32]. Synthetic
polymer membranes are typically composed of poly-lactide-co-glycolide and are
associated with lower bone volumes, poor tissue healing response, acidic degradation
products, and membrane exposure [35-40].
The problem with current GTR therapies for surgical treatment of periodontitis, is
that they are intended to restore the anatomical defect, but do not address the underlying
etiology of the disease. That is why for patients with chronic or unresolved periodontitis,
standard periodontal treatment is advocated before GTR or GBR therapy can begin [41].
This is costly and time-consuming for both the patient and physician. A better approach
would be to have a bioactive GTR material that can inhibit bacteria-induced sustained
host-inflammatory response during tissue healing and maturation. This expanded
function of the barrier membrane is a thin line to walk, because the transient expression
of inflammatory cytokines is absolutely necessary for bone healing and remodeling.
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However, sustained inflammation has been associated with a reduced bone formation
[42].
The sequence of cell signaling events that occur during periodontal tissue
destruction have been studied in depth [24, 43]. Lippopolysaccaride (LPS), which is the
primary component of gram-negative bacteria outer cell walls, is the major driver of
inflammatory cell recruitment and activation [24, 44]. Monocytes and activated
macrophages are stimulated by LPS to express nitric oxide (NO), interleukin-1β (IL-1β),
tumor necrosis factor-α (TNF- α), among a myriad of other pro-inflammatory cytokines,
which then recruit other cells to carry out tissue or bone breakdown. The primary culprits
in the breakdown of collagen and surrounding tissues are collagenase and matrix
metalloproteinases (MMPs) secreted by fibroblasts and polymorphonuclear leukocytes
(PMNs). Osteoclasts are also recruited for the breakdown bone in the presence of
receptor activator of nuclear factor-kappa B ligand (RANKL). Therapeutic approaches
which simply eliminate pathogenic bacteria are temporary ameliorations at best, since
after treatment has ended bacterial microflora can return. Furthermore, simple local
administration of antibiotic has shown no clinical benefit to patients undergoing GTR
procedures [45]. Next generation strategies involve the modulation of host-mediated
inflammatory response. Therapies which inhibit the release of pro-inflammatory
cytokines, or which inhibit the activation/differentiation of the involved the cell types, are
thought to be of benefit to patients with periodontitis [24].

Additionally, elevated

expression of NO in gingival and peri-apical tissues of patients with periodontitis has
been reported in several studies [23, 46]. These findings demonstrates that pathogenesis
of tissue destruction associated with periododntitis is, at least in part, dependent on NO
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signaling pathways. While systemic inhibition of NO signaling or iNOS expression is
clinically questionable, inhibition of NO in the periodontal tissues does appear to be a
valid target for the inhibition of periodontitis associated tissue destruction [23, 46].
Chitosan is a promising biomaterial for application as a GTR membrane because
it provides beneficial properties including increased bone formation and accelerated
wound healing [47]. Chitosan is the deacetylated form of the biopolymer chitin, which
possesses osteogenic properties [47, 48]. Chitosan’s chemical structure is N-acetylglucosamine –co- N-glucosamine copolymer, that is more than 50% deactylated. It can
be manipulated into a variety of constructs including films, beads, scaffolds, coatings,
fibers and nanofibers. Chitosan materials are derived from chitin, a biopolymer found in
crustaceans or some fungi. The biological properties and degradation rate of chitosan
materials can vary greatly by manipulating the degree of deacetylation (DDA), molecular
weight, and crystallinity of the polymer. Chitosan and its degradation products
(glucosamine sugars) are cytocompatible and non-acidic, unlike the degradation products
associated with synthetic polymers.
For use as GTR barrier membranes Kuo et al. investigated chitosan films gelated
with NaOH, and films crosslinked with Na 5 P 3 O 10 and Na 2 SO 3 and demonstrated the
ability to stimulate 21-31% more bone formation in rat calvaria than empty defect [49].
Films gelated with NaOH showed the greatest de novo bone formation [49]. Yeo et al.
evaluated chitosan wet-spun non-woven membranes (100 µm fiber) in canine one-wall
intrabony mandibular defects [50]. They reported that chitosan non-woven meshes
regenerated larger amounts of bone than biodegradable collagen membranes (Biomesh®,
Samyang Co) while having comparable soft tissue attachment and barrier function.
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Results at 8 weeks demonstrated that 42% of the bone height was restored by chitosan
membranes as opposed to 32% and 26% for collagen membrane and control (no
membrane), respectively. The wet-spinning and crosslinked film approaches
demonstrated promising results, but nanofabricated chitosan membranes would offer
additional benefits of permeability to nutrients and wastes, cell occlusion and biomimetic
scale for tissue integration [51-53], while maintaining the inherent beneficial properties
of chitosan biomaterials.
Materials can be fabricated into nano-fibrous constructs using a variety of
techniques including self assembly, phase separation and sugar leaching, and
electrospinning [54-59]. Electrospinning is a relatively inexpensive, simple, and reliable
method for the manufacture of polymer nanofibers, and can result in random fiber
orientation or highly aligned fiber orientation. The process works by using a large
voltage potential (typically 10-30 kV) to electrostatically charge a polymer solution [58].
This electrostatic charge causes chain repulsion forces within the polymer solution which
overcome the surface tension forces of that solution [58]. The result is a polymer fiber
which is extruded from the charged solution and sent into flight toward the collection
target. The collection target could be anything that is electrically grounded, including flat
plates, spinning drums, coagulation solutions, scaffold or implant materials, or even a
human hand. As the extruded fiber is driven toward the target, solvent evaporation and
fiber elongation result in solidified polymer fibers which have diameters typically < 150
nm [60].
Using electrospinning techniques, researchers have been able to make nanofibrous
constructs from synthetic polymers which regenerated dense cortical bone in rabbit tibia
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[61]. Shin et al. used electrospinning to fabricate chitosan biopolymer nanofibrous GBR
membranes to be biomimetic and provide cell occlusion [62]. They demonstrated that the
electrospun chitosan membranes facilitated more new bone formation in critical size bone
defects than control (empty defect) after 4 weeks in rabbit calvaria [62]. However, they
noted that their electrospun chitosan membranes fragmented after 8 weeks of
implantation in rat subcutaneous tissue. These studies demonstrated the potential of
degradable chitosan membranes to maintain graft space and regenerate bone with
minimal inflammatory response [49, 50, 62] but additional work on electrospun chitosan
membranes is needed to improve the clinical handle-ability, strength, and degradation
timeframe. In an effort to increase the strength and lengthen the degradation timeframe of
electrospun chitosan membranes, Schiffmann and Schauer used glutaraldehyde to
crosslink chitosan nanofibers [63, 64]. However, the glutaraldehyde crosslinking caused
an increase in the average fiber diameter, did not increase the ultimate tensile strength of
their chitosan membranes. Finally, they did not evaluate degradation or biocompatibility
of the resultant mats.
The ideal GTR material should be easy to handle and manipulate, have sufficient
strength to maintain the space of the graft site and to withstand suture or pin placement,
be cell occlusive, allow for the diffusion of nutrients and wastes, and degrade on a
timescale consistent with tissue healing and maturation. To meet these criteria, nonwoven chitosan mats were made by electrospinning using a slowly rotating circular target
to ensure random fiber orientation, and crosslinked using 5 mM or 10 mM genipin, a
natural crosslinking agent isolated from the fruit of the gardenia plant (Figures 1.1 and
1.2).
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Spinning Tip

Syringe Pump

Target

Figure 1.1 - Side view of the electrospinning setup for fabricating genipincrosslinked nano-fibrous chitosan mats.

Figure 1.2 – View of the collection target with nano-fibrous chitosan accumulation.
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Hypothesis
The use of a biodegradable, nano-fibrous, bioactive, antimicrobial, chitosan mats
strengthened by genipin crosslinking will result in improved clinical outcomes compared
to current GTR membrane therapies by stimulating healing, reducing pathogenic bacteria,
and reducing host mediated inflammation. Specifically, genipin-crosslinked electrospun
chitosan should exhibit evidence of chemical crosslinking and should have a higher
tensile and suture pullout strength than uncrosslinked membranes. Genipin-crosslinked
electrospun chitosan membranes should degrade on a timescale consistent with tissue
healing and bone maturation. Electrospun chitosan mats should not exhibit cytotoxic
effects to osteoblasts, fibroblasts, or monocyte cells. Genipin-crosslinked electropun
membranes should maintain the capacity to deliver antibiotics or growth factors to the
graft site as compared to uncrosslinked membranes. Finally, genipin-crosslinked
electrospun chitosan membranes should be able to reduce LPS-induced monocycte
activation in a manner similar to uncrosslinked membranes.

9

CHAPTER 2. Journal submission to the Journal of Tissue Engineering and
Regenerative Medicine
Novel naturally crosslinked electrospun nano-fibrous chitosan mats for guided bone
regeneration membranes: material characterization and cytocompatibility.
Authors: Peter A. Norowski Jr, Tomoko Fujiwara, William C. Clem, Pradeep C.
Adatrow, Eugene C. Eckstein, Warren O. Haggard, Joel D. Bumgardner.
Abstract: Guided bone regeneration (GBR) barrier membranes are used to prevent soft
tissue infiltration into the graft space during dental procedures that involve bone grafting.
Chitosan materials have shown promise as GBR barrier membranes due to their
biocompatibility and predictable biodegradability, but degradation rates may still be too
high for clinical applications. In this study, chitosan GBR membranes were electrospun
using chitosan (70% deacetylated, 312 kDa, 5.5 w/v%) with or without the addition of 5
or 10 mM genipin, a natural crosslinking agent, in order to extend the degradation to
meet the clinical target timeframe of 4-6 months. Membranes were evaluated for fiber
diameter, tensile strength, biodegradation rate, bond structure, and cytocompatibility.
Genipin addition, at 5 or 10 mM, slightly reduced the fiber diameter from 165-228 nm for
uncrosslinked to 142-197 nm. Crosslinking, examined by Fourier transform infrared
spectroscopy, showed a decrease in N-H stretch as genipin levels were increased.
Genipin-crosslinked mats exhibited only 22% degradation based on mass loss as
compared to 34% for uncrosslinked mats at 16 weeks in vitro. The ultimate tensile
strength of the mats was increased by 165% to 32 MPa with 10 mM crosslinking as
compared to uncrosslinked mats. Finally, genipin-crosslinked mats supported the
proliferation of SAOS-2 cells in a 5 day growth study, similar to uncrosslinked mats.
Results suggest that electrospun chitosan mats may benefit from genipin crosslinking and
have the potential to meet clinical degradation timeframes for GBR applications.
10

1. Introduction
In dental applications, guided bone regeneration (GBR) is a surgical technique
used to direct the formation of bone during augmentation procedures where a barrier
membrane is used to exclude the soft tissues from the bone graft space. Current clinically
used membranes made from expanded polytetrafluoroethylene (ePTFE), a nondegradable woven material, require a second surgery for removal and are reported to have
exposure/infection rates as high as 20-44% [1, 2]. The removal surgery may disrupt
healing in the graft area and is a financial and physical burden to both the patient and
physician. For this reason, many clinicians have begun to use degradable membranes
which do not require removal [3]. Commercially available biodegradable membranes are
typically made from porcine or bovine collagen. However, the degradation of these
collagen materials is rapid and unpredictable and they may not maintain barrier function
for the full healing and regeneration period of 4-6 months [4]. Collagen membranes,
crosslinked with glutaraldehyde, have slower degradation rates, but they also have poor
tissue response, become exposed more often [5] and elicit less bone formation than
uncrosslinked collagen membranes [4]. Additional problems with collagen and ePTFE
membranes include infection, wound dehiscence and membrane exposure [3, 6, 7] and
premature membrane degradation [4] especially when exposed to the oral cavity [5].
Chitosan is a linear biopolymer composed of more than 50% N-glucosamine units
in a N-acetyl-glucosamine –co- N-glucosamine copolymer. Chitosan materials have
shown great potential in GBR applications because of their biocompatibility, controllable
degradation, and non-toxic degradation products [8-10] and have been manufactured into
fibers and sheets using a variety of techniques including electrospinning, wet-spinning,
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and solution casting [8-13]. Electrospinning, which uses a high voltage source to
manufacture polymer fibers, is well suited for the production of fibrous membranes
because it is relatively cheap, simple, and can reliably reproduce fibers in the nano-range.
Nano-fibrous membranes are particularly advantageous because they allow fluid and
nutrient exchange through the membrane, mimic the topology of the extracellular matrix,
and are cell occlusive. The extruded polymer fibers, which solidify as they are collected
on the electrically grounded target, are deposited in random fashion until they collect into
a non-woven randomly oriented fiber mat. This process yields pores that are too small to
allow cellular infiltration.
Chitosan may be electrospun using specific solvents such as 1,1,1,3,3,3hexafluoroisopropyl alcohol (HFIP) or trifluoroacetic acid (TFA) or is spun using copolymer mixtures with polyethylene oxide (PEO), polyvinyl alcohol (PVA), or collagen
[14]. Typically electrospun fibers have a mean diameter of ≤ 100 nm, but can vary
widely with diameters as large as 1 µm, depending upon a number of factors such as
polymer wt.%, polymer molecular weight, viscosity, voltage, temperature, and solvent
properties such as surface tension to name a few [15].
Kuo et al. investigated chitosan films gelated with NaOH, and films crosslinked
with Na 5 P 3 O 10 and Na 2 SO 3 for use as GBR membranes and demonstrated good
mechanical properties and were able to stimulate the formation of bone in rat calvaria
better than controls (empty defect) [8]. Yeo et al. evaluated chitosan wet-spun nonwoven membranes (100 µm fiber) in canine one-wall intrabony mandibular defects [10].
They reported that chitosan non-woven meshes regenerated larger amounts of bone than
biodegradable collagen membranes (Biomesh®, Samyang Co) while having comparable
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soft tissue attachment and barrier function, and that, at 8 weeks, 42% of the bone height
was restored by chitosan membranes as opposed to 32% and 26% for collagen membrane
and control (no membrane), respectively. Though these results were promising, the wetspinning approach did not offer all of the advantages of nanofabricated membranes such
as cell occlusion and biomimetic scale. Using electrospinning techniques, Shin et al.
made nanofibrous GBR membranes to be biomimetic and provide cell occlusion [9].
They demonstrated that the electrospun chitosan membranes facilitated more new bone
formation in critical size bone defects than control (empty defect) after 4 weeks in rabbit
calvaria [9]. However, they noted that their electrospun chitosan membranes fragmented
after 8 weeks of implantation in rat subcutaneous tissue. These studies demonstrated the
potential of degradable chitosan membranes to maintain graft space and regenerate bone
with minimal inflammatory response [8-10] but additional work is needed to improve the
clinical handle-ability, strength, and degradation timeframe of electrospun chitosan
membranes.
In an effort to increase the strength and degradation timeframe of electrospun
chitosan membranes, Schiffmann and Schauer used glutaraldehyde to crosslink chitosan
nanofibers [12, 13]. However, the glutaraldehyde crosslinking caused an increase in the
average fiber diameter, did not increase the ultimate tensile strength of their chitosan
membranes, nor did they evaluate degradation or biocompatibility of the mats.
In this study, the natural crosslinker genipin, which is isolated from the fruit of the
gardenia plant, was used to crosslink chitosan nanofibrous mats. Studies have shown that
chitosan and gelatin membranes were more biocompatible, less inflammatory, and
resulted in faster healing times when crosslinked with genipin instead of glutaraldehyde
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[16-18]. Our goal was to extend the degradation of the chitosan membrane to the
clinician suggested period of 4-6 months. Our hypothesis is that genipin-crosslinked
chitosan mats will exhibit improved mechanical strength, extended degradation
timeframe, and little or no cytotoxicity when compared to uncrosslinked chitosan mats.
2. Materials and Methods
2.1 Electrospinning procedure
To make electrospun chitosan nanofibrous mats a 5.50wt% chitosan solution in 70%
trifluoroacetic acid and 30% methylene chloride was gently mixed overnight. Genipin is
mixed into the polymer solution 30 minutes prior to the start of electrospinning at a
concentration of 0, 5, or 10 mM. The solution was loaded into a plastic 10 mL syringe
with a blunt 20G, 3.81 cm stainless steel needle tip. The syringe was loaded into a
syringe pump and the flowrate set to 20 µL/min. The solution was electrospun at 25 kV
and the fibers were collected on a non-stick aluminum foil target (38.1 cm diameter disc),
positioned 15 cm from needle tip and rotated at 8.4 rpm by an AC motor to ensure even
and random distribution of fibers. The electrospinning apparatus was housed inside of a
ventilated box, which was vented to the fume hood. After electrospinning, the nanofibrous mat was put under vacuum overnight to remove residual solvent, removed from
the foil, and then neutralized in room temperature 5M Na 2 CO 3 (saturated solution) for 3
hours [11]. The membrane was then rinsed with deionized water until neutral. After
drying at ambient conditions, mats were sterilized using ethylene oxide gas.
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2.2 Scanning electron microscopy (SEM)
SEM was used to view the morphology and determine the diameter of the electrospun
fibers from two different mats of each type. To view fibers, representative 1 cm2 samples
were cut and then coated with 10 nm of gold-palladium to aid in imaging and reduce
charging. All images were collected using Philips XL 30 ESEM (FEI Co., Hillsboro,
OR). Fiber size was determined from 4 locations and viewed at 5000X for each sample
and measuring diameters standard image analysis techniques.
2.3 Mechanical Testing.
Mechanical testing was performed to determine ultimate tensile strength of the
electrospun mats as an indicator of clinical handle-ability. Dog bone shaped specimens
were cut from mats using a custom punch. The dimensions of the gauge length of the dog
bone specimen were measured with digital caliper and were approximately 13x3.7x0.12
mm. Tensile testing (n=4) of dry dog-bone specimens was carried out using an InstronTM
model 4465 mechanical test frame (Norwood, MA, USA) with a 500 N load cell and an
extension rate of 1 mm/min.
2.4 Fourier Transform Infrared Spectroscopy (FTIR)
In order to assess the level of crosslinking that occurred we examined the bond structure
of the chitosan membranes by attenuated total reflectance FTIR. Spectra were collected
from neutralized membrane samples (1 cm2; n=4) on a Nicolet FTIR spectrometer in
absorbance mode. Membranes and background were scanned 64 times with a resolution
of 4 cm-1 according to ASTM F2103-01 (2009).
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2.5 In vitro biodegradation
To determine degradation profile of crosslinked and uncrosslinked electrospun
membranes, samples 3 cm2 in size were incubated at 37 oC in PBS containing 100 µg/mL
lysozyme, supplemented with 500 I.U./mL penicillin, 500 µg/mL streptomycin, and 25
µg/mL amphotericin-B and the change in mass was recorded at 1, 2, 3, 4 and 16 weeks.
This study was performed in PBS containing 100µg/mL lysozyme, a level much higher
than physiological conditions. A high level of lysozyme was used in this study to
accelerate degradation and differentiate any possible differences in biodegradation caused
by crosslinking of the chitosan polymer. It was not intended to be predictive of clinical
performance. Results are presented as the mass fraction remaining. Separate independent
samples of 4 membranes per group were taken at each timepoint.
2.6 In vitro cell viability and proliferation.
SAOS-2 human (Cat. No. HTB-85, ATCC, Manassas, VA, USA) osteoblastic cells were
seeded on uncrosslinked and crosslinked nanofibrous membranes mounted in 24-well
size CellCrownTM culture inserts (Scaffdex, Tampere, Finland).

CellCrownTM inserts

were used to keep membranes from floating in culture wells. Membranes were rinsed in
culture media 4 times and then seeded at 1x104 cells per membrane. Cells were also
seeded onto 24-well tissue culture plastic as a positive control. Cells were grown in
McCoy’s 5a medium supplemented with 10% FBS and 500 I.U./mL penicillin, 500
µg/mL streptomycin, and 25 µg/mL amphotericin-B. Proliferation was measured at days
1, 3, and 5 (n=4 per group per time point) using Cell Titre GloTM luminescent cell
viability assay (Promega, Madison, WI, USA). The assay measures the amount of light
produced based on the oxidation of ATP, which is proportional to the total number of
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cells, in the luciferin-luciferase reaction. Cell number was determined by means of a
standard curve of SAOS-2 cells ranging from 5x103 to 2x105 cells/well seeded on tissue
culture plastic twelve hours before assay. Cell viability and morphology was also
observed by fluorescent microscopy using Live-Dead® stain (Molecular Probes, Eugene
OR, USA). Images of cells growing on membranes were obtained by fluorescent
microscopy (Nikon Eclipse TE300, Tokyo, Japan).
Statistically significant differences were detected by ANOVA followed by
Student-Neuman-Kools (SNK) post-hoc test to determine where differences existed
between groups. Statistical significance was declared at p<0.05.
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3. Results
Electrospun mats had a mean fiber diameter in the nano-range. Representative images
are shown in Figure 1 and the fiber diameter from each of the 2 mats per group is
summarized in Table 1. In general, genipin addition to the electrospinning solution
resulted in smaller diameter fibers as compared to chitosan fibers electrospun without
genipin.
The results of the degradation study are shown in Figure 2. Statistical analyses
showed that there was a significant change in mass for all mats over time (p<0.05) and
between groups (p<0.05). Uncrosslinked chitosan mats resulted in the greatest loss in
mass and 10 mM genipin crosslinked mats resulted in the least loss. While significant
differences may not exist between all groups at each time point, at 16 weeks (4 months),
uncrosslinked mats had lost (34%) significantly more mass than 10 mM crosslinked mats
(22%), while 5 mM (28%) was not significantly different from either.
Mechanical testing revealed that the tensile strength is significantly increased
upon crosslinking with genipin (Figure 3). The ultimate tensile strength was 12.3 ± 5.0
MPa for uncrosslinked chitosan mats, which increased to 22.2 ± 6.8 and 32.2 ± 8.1 MPa
for crosslinking with 5 and 10 mM genipin, respectively.
Representative FTIR spectra of the uncrosslinked mat and of each level of genipin
crosslinked chitosan mats are shown in Figure 4. FTIR spectra gathered from all groups
of electrospun mats exhibited amide I (1651 cm-1), amide II (1586 cm-1), amide III (1321
cm-1) and C-O-C (1032, 1082, 1152 cm-1) peaks typical of chitosan structure. The N-H
stretch peak is found at 3372 cm-1 atop the larger and more broad O-H stretch peak and is
interpreted as the free amino groups present on the chitosan polymer. The height of the
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N-H stretch peak decreased by 60% and 86% for chitosan mats electrospun with 5 mM
and 10 mM genipin, respectively.
There were no statistical differences in the 5 day growth of cells on crosslinked
membranes as compared to uncrosslinked membranes (Figure 5). Osteoblastic cells on
all membrane types were viable and had a low proportion of non-viable cells as shown by
Live-Dead® stain (Figure 6). No differences in morphology or viability of the cells,
based on visual inspection, on the membranes were observed.

Table 1 – Fiber diameters ± standard deviation of electrospun chitosan mats as
measured via image analysis at 5000X magnification.
Uncrosslinked
5 mM genipin
10 mM genipin

Mat 1 fiber diameter (nm)
162 ± 98
142 ± 90
142 ± 56

Mat 2 fiber diameter (nm)
228 ± 116
160 ± 61
197 ± 68

Figure 1 – representative SEM images of A) uncrosslinked, B) 5 mM genipin
crosslinked and C) 10 mM genipin crosslinked chitosan fibers.
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Figure 2 – In vitro biodegradation measured by mass loss over a 16 weeks in
PBS+100 µg/mL lysozyme at 37oC. The mass fraction remaining is plotted against
time in weeks. The * and # denote statistical significance (p<0.05) as determined by
ANOVA and SNK post-hoc test.

Figure 3 – Ultimate tensile strength of the dry electrospun membranes (n=4) *
indicates significant difference p<0.05.
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Figure 4 – FTIR spectra from uncrosslinked chitosan (red), 5 mM crosslinked
chitosan (blue) and 10 mM crosslinked chitosan (green). Note the diminishing N-H
stretch peak at 3372 cm-1, which is the narrow peak atop the larger O-H stretch
peak. With higher levels of crosslinking the free amino peak is decreasing
indicating that the genipin is crosslinking at that site. Other labeled peaks are
associated with the glucosamine structure of chitosan.
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Figure 5 – The number of SAOS cells present on the membrane after 1-5 days of
culture determined by a standard curve of cell densities seeded 12 hours before
reading. No significant difference were found (n=4).

Figure 6: Live dead stain of SAOS-2 cells on day 5 at 40X magnification. A)
Uncrosslinked chitosan B) 10 mM genipin crosslinked. Note the large number of
green viable cells. Results were similar for 5 mM (not shown).
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4. Discussion
Chitosan has shown promise as a GBR membrane material, but degradation has not been
optimized to maintain effective barrier function for the target 4-6 months of healing. In
this study, we investigated the hypothesis that genipin crosslinking of electrospun
chitosan would improve mechanical properties, prolong degradation timeframe, and
exhibit cytocompatibility. The results of this work support this hypothesis and showed
that crosslinking electrospun chitosan with genipin slowed degradation of mats by 17 %
and improved initial mechanical properties by 165% percent as compared to
uncrosslinked mats, and that crosslinked mats were compatible with cells and did not
impact cellular growth. The addition of genipin also had a slight effect on the mean
nanofiber diameter of the electrospun mats.
In this study, we electrospun 5.50% chitosan in 70% TFA and 30% DCM. Our
study found the average nanofiber diameter to be 162-228 nm for uncrosslinked chitosan
and slightly lesser diameters (142-197 nm) for crosslinked membranes. These results are
in agreement with others who electrospun chitosan using similar methods and found
mean fiber diameters between 77 to 330 nm [12, 19, 20]. The TFA solvent forms salts
with the amino group of the chitosan molecules which destroys the rigid interactions
between chains thus allowing electrospinning [14]. As the polymer is crosslinked with
genipin, there is a decrease in free amino groups, which displaces the TFA salt and alters
polymer chain interactions thus resulting in thinner fibers being formed as compared to
the uncrosslinked material.
To crosslink chitosan nano-fibers, other researchers have added small amounts of
glutaraldehyde liquid to the chitosan polymer solution [13]. They found that adding
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glutaraldehyde to the chitosan solution increased the mean fiber diameter from 77 ± 29
nm for as spun fibers to 128 ± 40 nm. Furthermore, when glutaraldehyde vapor was
used to crosslink chitosan fibers after electrospinning, the diameter increased even more
to 172 ± 75 nm [12]. The crosslinking with glutaraldehyde also resulted in significantly
decreased mechanical strength of the chitosan mats [12]. Our study demonstrated that
when genipin was used to crosslink the fibers, there was no increase in fiber diameter,
and more importantly, there was an increase in mechanical strength. The results from our
study indicate that genipin helps to maintain small fiber diameters and to retain the
desired topographical scale and cell occlusive properties of the mat, as well as maintain
adequate mechanical properties for clinical handling and manipulating the mats.
The degradation study demonstrated that genipin crosslinking may be used to
extend the degradation of electrospun chitosan membranes. The 5 mM and 10 mM
crosslinked membrane groups showed a slower degradation rates with 8-17% less mass
loss, respectively, at 16 weeks as compared to uncrosslinked mats. These data provide
evidence genipin crosslinking reduces rate of degradation of membranes and that all
groups meet the 4-6 month target timeframe. However, it is also important to note that
our uncrosslinked membranes usually fragmented sometime after 4 weeks in solution
while our crosslinked membranes did not. This indicates that even though uncrosslinked
mats may have degradation rates on par with the 4-6 month time frame, crosslinked mats
may perform better in GBR applications since fragmented uncrosslinked membranes
would be unable to provide an effective barrier function. These in vitro data are
predictive of the chitosan mats meeting degradation target timeframes, and that the
genipin crosslinked membranes will remain intact. Differences in degradation rates
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would be expected in vivo, and this in vitro evaluation should only be used to rank the
degradation profiles.
Sangsanoh et al. evaluated the in vitro weight loss of electrospun chitosan
membranes over 12 weeks and had comparable results using PBS without lysozyme [11].
However, they observed a slightly slower degradation rate with 14 % mass loss at 4
weeks and 16.5% mass loss at 12 weeks for uncrosslinked mats, while we observed 21 %
mass loss at 4 weeks and 34% mass loss at 16 weeks for uncrosslinked mats. These
differences are most likely due to the presence of lysozyme in our PBS solution, the
primary enzyme responsible for chitosan degradation [21]. In vivo studies by Shin et al.
reported membrane fragmentation and rapid degradation after 8 weeks when
uncrosslinked electrospun chitosan mats made using HFIP were implanted in rat
subcutaneous tissue [9]. Our electrospun membranes, and those evaluated by Sangsanoh
et al., were constructed using TFA/DCM solvent system and used higher weight percent
chitosan (5.5% and 7% vs. 1.5% (w/v) chitosan) and were neutralized, so our results may
not be directly comparable. It is important to note that neutralization may play a large
role in the degradation of these mats by causing protonation of the chitosan polymer.
Protonation grants a positive charge to the polymer and renders it insoluble in aqueous
solutions, which probably contributes to the slower degradation.
The strength of the mats in this study without crosslinking was 3 times greater
than those reported by Schiffmann et al. who studied un-neutralized electrospun chitosan
mats with and without crosslinking using glutaraldehyde. Additionally, Schiffmann et al.
used a 2.7 % (w/v) chitosan solution, 83% DDA, ~190-310 kDa, a spinning distance of
6.4 cm, and pure TFA solvent, while this study evaluated 5.5% (w/v) chitosan solution,
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70 % DDA, 312 kDa, a spinning distance of 15 cm, and 70/30 TFA/DCM solvent
mixture. The previous studies by Schiffmann et al. showed that using glutaraldehyde to
crosslink decreased the ultimate tensile strength from 4 MPa to around 1 MPa and
increased the brittleness of the membrane [12]. Our results demonstrated significantly
higher ultimate tensile stress when genipin was used to crosslink from 12 MPa for
uncrosslinked to 32 MPa for 10 mM crosslinked (Figure 3). The fiber diameters, when
comparing uncrosslinked chitosan mats, differed between the two methods (77 vs 198
nm). The observed differences in mechanical strength of uncrosslinked membranes
between the current study and the one performed by Schiffmann et al. could be attributed
to the differences in electrospinning parameters, fiber size, or to the neutralization
process. The increase in tensile strength observed in this study was attributed to the
genipin crosslinking of the chitosan material (as evidenced by FTIR), was significant for
the 10 mM concentration and almost significant for the 5 mM concentration (p=0.06).
These results indicate that genipin crosslinking of chitosan mats is an effective method to
increase the ultimate strength for improved clinical handle-ability.
Under the acidic crosslinking conditions of this study, genipin will bind the amino
group on the chitosan chain, to which another genipin molecule will attach, to form
dimer, trimer and tetramer bridges of genipin between and within chitosan chains [16,
17]. Therefore, we would expect to see a decrease in the amount of free amino groups
present when genipin crosslinking occurs. FTIR did show that peaks associated with NH stretch at 3372 cm-1 were diminished in intensity as the level of crosslinking increased,
indicating that genipin was binding chitosan at the amino group. From the normalized
absorbance spectra we can see the height of the N-H peak decreased by 60% for 5 mM
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genipin crosslinked and decreased by 86% for 10 mM crosslinked. This decrease
indicates that genipin is interacting with the chitosan at the amino group in a dose
dependent manner. Thus, crosslinking is the mechanism by which we observed the
proportional increase in mechanical strength and degradation time with genipin
concentration in the electrospinning solution.
The five-day cell growth study demonstrated that the chitosan membrane is
cytocompatible and will not inhibit osteoblast proliferation. The proliferation and
viability was unaffected by crosslinking degree and the cell morphology was mostly
cuboidal but there was some cell spreading along the fibers in the less densely populated
areas on the membrane (Figure 6B). The overwhelming majority of cells were healthy
and viable. These results are in agreement with Sangsanoh et al. who evaluated Schwann
cell proliferation on uncrosslinked chitosan films and electrospun fibers over a five-day
period. Their study demonstrated similar capacity for the chitosan films and fibers to
support cell proliferation over the 5 day period and mostly cuboidal cell morphology
[19]. Our results illustrate for the first time that genipin can be used to crosslink
electrospun chitosan fibers to increase the mechanical properties, maintain nano-fibrous
morphology, and support cellular proliferation.
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5. Conclusion
These results suggest that electrospun chitosan mats may benefit from crosslinking with
genipin. This study has demonstrated that electrospun chitosan mats, with and without
genipin crosslinking, have mechanical properties, degradation rate, and cytocompatibility
which are sufficient for GBR applications. Crosslinking with genipin may offer increased
mechanical strength and increased cycompatibility compared to other crosslinkers. These
findings warrant expanded in vitro and in vivo investigations into genipin-crosslinked
electrospun chitosan mats for GBR applications.
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CHAPTER 3: Submission to the Journal of Biomedical Materials Research:
Part A
Suture pullout strength and in vitro fibroblast and RAW 264.7 monocyte
biocompatibility of genipin crosslinked nano-fibrous chitosan mats for guided tissue
regeneration.
Authors: Norowski, PA, Mishra, S, Adatrow, PC, Haggard, WO, Bumgardner, JD.

Abstract: Chitosan materials have been advocated for guided tissue regeneration (GTR)
applications because of their biocompatibility, degradability, wound healing and
osteogenic properties. In this study, electrospun chitosan membranes, crosslinked with 5
mM or 10 mM geinipin, a natural crosslinker derived from the gardenia plant, were
evaluated for suture pullout strength, crystallinity and cytocompatibility with normal
human dermal fibroblast and TIB 71TM RAW 264.7 monocyte cells. Ultimate suture
pullout strength was significantly lower (51-67%) than that of commercially available
collagen membranes (BioMend Extend, Zimmer Dental). Crystallinity of the electrospun
chitosan mats decreased upon crosslinking by 14-17% (p=0.013). Uncrosslinked and
crosslinked chitosan mats were biocompatible and supported fibroblast cell proliferation
over 9 days without allowing cell penetration. Finally, chitosan membranes inhibited
lippopolysaccharide (LPS)-induced RAW 264.7 nitric oxide production by 59-67% as
compared to tissue culture plastic and collagen membrane. Membranes demonstrated
cytocompatibility with fibroblasts and did not activate monocytes to produce proinflammatory factors in vitro. In monocyte cultures with LPS, activation of monocytes
grown on electrospun chitosan membranes was reduced as indicated by NO production
normalized to cell number as compared to tissue culture plastic and commerciallyavailable glutaraldehyde-crosslinked collagen membrane controls. Improvements are
needed in the tear strength of electrospun chitosan membranes for clinical application.
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However, the ability of chitosan to inhibit LPS-induced NO expression in monocytes
may be beneficial in the treatment of patients with chronic periodontitis who are
undergoing GTR procedures.
INTRODUCTION
Guided tissue regeneration (GTR) is a surgical technique used to direct the formation of
bone by using a barrier membrane to exclude the faster healing soft tissues from the graft
site. While the use of barrier membranes is expanding into other surgical arenas, in
dentistry, they are primarily used to treat intrabony defects caused by periodontal lesions
around teeth or implants. In oral/maxillofacial surgery they are used to protect the graft
space in larger bone defects caused by bone resection, bone atrophy, trauma, or
osteotomy. Currently utilized materials for GTR are non-ideal because they either
require an additional removal surgery or they do not resorb predictably in a manner that
matches the surrounding tissue remodeling rates. Ideally, GTR membranes provide
effective barrier function to maintain tissue spaces, allow for diffusion of nutrients,
wastes and signaling factors during healing and degrade on a time scale consistent with
healing and tissue maturation.
Chitosan is a linear biopolymer composed of more than 50% N-glucosamine units
in a N-acetyl-glucosamine –co- N-glucosamine copolymer. Chitosan materials have been
advocated for GTR applications because of their biocompatibility, controllable
biodegradation, and non-toxic degradation products1-3 and have been manufactured into
fibers and sheets using a variety of techniques including electrospinning, wet-spinning,
and solution casting.1-6 Electrospinning, which uses a high voltage source to fabricate
polymer fibers, is well suited for the production of fibrous membranes because it is
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relatively inexpensive, simple, and can reliably reproduce fibers in the nano-range.
Nano-fibrous membranes are particularly advantageous in GTR because they allow fluid
and nutrient exchange through the membrane while maintaining a porosity that is small
enough to be cell occlusive.7-10 Electrospun materials are also thought to mimic the
topology of the extracellular matrix, promoting cell attachment and proliferation.11-13
Using electrospinning techniques, Shin et al. made nanofibrous GTR membranes
to be biomimetic and provide cell occlusion.2 They demonstrated that the electrospun
chitosan membranes facilitated more new bone formation in critical size bone defects
than control (empty defect) after 4 weeks in rabbit calvaria.2 However, they noted that
their electrospun chitosan membranes fragmented after 8 weeks of implantation in rat
subcutaneous tissue. These studies demonstrated the potential of degradable chitosan
membranes to maintain graft space and regenerate bone with minimal inflammatory
response1-3 but improvements must be made in the clinical handle-ability and strength of
electrospun chitosan membranes in order to improve clinical outcomes.
Glutaraldehyde crosslinking has been advocated for increased stability and
strength of electrospun chitosan membranes but caused an increase in the average fiber
diameter, did not increase the ultimate tensile strength of the chitosan membranes, nor
did the investigators evaluate degradation or biocompatibility.5,6 Recently, we have
shown that crosslinking electrospun chitosan membranes with 5 or 10 mM genipin
decreased in vitro degradation kinetics to have 78%-66% percent mass remaining at 16
weeks which would predict a degradation timeframe that is on target with
recommendations by clinicians. Additionally, the genipin crosslinking increased tensile
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strengths of the electrospun mats by 260% which were also cytocompatible with SAOS-2
osteoblastic cells [Norowski et al., in review].
Periodontitis is a chronic inflammatory disease in which the host response is
primarily driven by the presence of lippopolysaccharide (LPS) which causes monocyte
recruitment and differentiation into macrophages and pre-osteoclasts, ultimately leading
to bone and soft tissue breakdown.14 Patients with periodontitis also have elevated
expression of nitric oxide (NO) in the gingival and periodontal ligament tissues.15-17
While currently available GTR membrane materials do not actively participate in the
treatment of periodontitis, bioactive materials may provide advantages if they are able to
lessen or inhibit tissue destruction associated with LPS-induced chronic inflammation or
inhibit NO production.15-17 Chitosan oligosaccharide and other chitinous constructs have
been shown to inhibit NO production by RAW 264.7 monocytes and other inflammatory
cells.18-21
In this study, the natural crosslinker genipin, which is isolated from the fruit of the
gardenia plant, was used to crosslink chitosan nanofibrous mats. Past studies have shown
that chitosan and gelatin membranes were more biocompatible, less inflammatory, and
resulted in faster healing times when crosslinked with genipin instead of
glutaraldehyde.22-24 Our goal was to characterize genipin-crosslinked electrospunchitosan membranes and evaluate their potential performance as GTR membranes as
compared to commercially available degradable collagen membranes. Electrospun
chitosan membranes should not exhibit cytotoxicity to human fibroblast cells nor activate
monocyte inflammation.
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MATERIALS AND METHODS
Electrospinning procedure
Nanofibrous chitosan mats with random fiber orientation were fabricated by
electrospinning. Briefly, a 5.50(wt/v)% chitosan solution in 70(v/v)% trifluoroacetic acid
and 30(v/v)% methylene chloride was gently mixed overnight. Genipin was mixed into
the polymer solution 30 minutes prior to the start of electrospinning at a concentration of
0, 5, or 10 mM. The solution was loaded into a 10 mL syringe with a blunt 20G, 3.81 cm
stainless steel needle tip. The syringe was loaded into a syringe pump and the flowrate
set to 20 µL/min. The solution was electrospun at 25 kV and the fibers were collected on
a non-stick aluminum foil target (38.1 cm diameter circular disc), positioned 15 cm from
needle tip and rotated at 8.4 RPM by an AC motor to ensure even and random
distribution of fibers. The electrospinning apparatus was housed inside a ventilated box,
which was vented to the fume hood. After electrospinning, the nano-fibrous mat was put
under vacuum overnight to remove residual solvent, carefully removed from the foil, and
then neutralized in room temperature 5M Na 2 CO 3 (saturated solution) for 3 hours.4 The
membrane was then rinsed with deionized water until neutral. After drying at ambient
conditions, mats were sterilized using ethylene oxide gas.
Suture pullout strength
Suture pullout tests were performed to determine the tear strength of the membranes.
Membrane specimens were prepared to be 10 mm wide and about 40 mm long. As a
comparison to currently-available clinically-used materials, electrospun mats were tested
against a degradable collagen membrane crosslinked with glutaraldehyde (Biomend
Extend, Zimmer Dental, Warsaw IN, USA). A single suture was made 5 mm from the
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top edge and 5 mm from each side. The suture was a 70 cm general closure
monofilament polydioxanone (PDS II, Ethicon, Z-341) with taper ct-1 needle and 1 (4.0
metric) gauge. The suture was left un-knotted but was affixed to the upper claw of the
InstronTM model 4465 mechanical test frame (Norwood, MA, USA) (Figure 1). Suture
pullout testing (n=4) of dry specimens was carried out with a 50 N load cell and an
extension rate of 1 mm/min. Maximum load was recorded in Newtons (N) and
normalized to membrane thickness.
X-ray diffraction (XRD)
Crystallinity measurements were made using Bruker D8 Advance XRD. Chitosan
membranes were ground into a fine powder with a mortar and pestle, after submersion in
liquid nitrogen. Powders were scanned in grazing angle reflection mode and data were
collected with 2θ from 4 to 30. Crystallinity index was determined by taking the
difference of the peak intensity that occurs at 2θ=20 and the lowest point of the baseline
(amorphous region) of the spectrum (2θ=10) then normalizing to the peak intensity.25
Molecular weight measurement by size exclusion chromatography coupled with
multi-angle static light scattering (SEC-MALS)
Chitosan samples were run at 30 oC, through 2 TSK gel columns in series (polymer range
100,000-900,000) with a mobile phase of 0.15 M HAc and 0.1 M NaAc (pH 5). Chitosan
was dissolved at 1 mg/mL, filtered using a 0.45 µm pore size, and injected using 50 µL
injection volume. The molecular weights, Mw and Mn, were determined using multiangle static light scattering (Wyatt, Dawn HELEOS II) and a refractive index detector
(Varian, Prostar 450). The dn/dC for chitosan was entered as 0.163 mL-1 as previously
reported.26 All analysis performed using ASTRA software (Wyatt Technologies Corp.).
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Measurements were made on the starting material and the uncrosslinked membrane, but
no measurements could be made of crosslinked membranes as they did not go into
solution in the mobile phase, even with increased acidity.
Fibroblast cytocompatibility
Normal human dermal fibroblasts (NhDF) (ATCC No. PCS-201-010, Manassas, VA,
USA) cells were seeded on uncrosslinked and crosslinked nanofibrous membranes
mounted in 24-well size CellCrownTM culture inserts (Scaffdex, Tampere, Finland).
CellCrownTM inserts were used to keep membranes from floating in culture wells and to
provide a uniform and flat surface for cell culture. Membranes were rinsed in culture
media 4 times and then seeded at 1x105 cells per membrane. Cells were also seeded onto
24-well tissue culture plastic as a positive control. Cells were grown in Dubulco’s
modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and
500 I.U./mL penicillin, 500 µg/mL streptomycin, and 2.5 µg/mL amphotericin-B.
Proliferation was measured at days 1, 5, and 9 (n=4 per group per time point) using Cell
Titre GloTM luminescent cell viability assay (Promega, Madison, WI, USA). The assay
measures the number of cells based on the amount of light produced from the oxidation
of intracellular ATP in the luciferin-luciferase reaction. Cell number was determined by
means of a standard curve of NhDF cells in 24 well plates.
Monocyte activation
TIB 71TM RAW 264.7 monocyte cells were seeded on uncrosslinked, genipincrosslinked, and commercially available collagen membranes (Biomend Extend, Zimmer
Dental, Warsaw In) or tissue culture plastic as control. Scaffolds (n=4) were seeded at
1.0x106 cells per scaffold. Cells were grown in DMEM supplemented with 10% FBS,
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and 500 I.U./mL penicillin, 500 µg/mL streptomycin, and 25 µg/mL amphotericin-B. All
treatment groups were grown in the presence or absence of 1 µg/mL lipopolysaccaride
(LPS, Escherichia coli derived). LPS is known to stimulate monocyte cells to produce
the reactive oxygen species, nitric oxide (NO), a potent signaling and pro-inflammatory
molecule. The cumulative levels of NO produced by the cells on the membranes was
measured via the Griess Reagent (Promega, Madison, WI, USA) as an indicator of
monocyte stimulation on days 1, 2 and 3. The viability of cells was measured at the
terminal timepoint (day 3) to verify cell number using Cell Titre GloTM luminescent cell
viability assay. Cell number was determined by means of a standard curve of RAW
264.7 cells in 24 well plate.
Statistically significant differences were detected by one-way or two-way
ANOVA followed by Student-Neuman-Kools (SNK) post-hoc test to determine where
differences existed between groups. Statistical significance was declared at p<0.05.
RESULTS
Suture pullout tests were carried out using monofilament polydioxanone suture
(Figure 1). Specimens showed predictable tear patterns that extended upwards toward
the superior edge of the specimen (Figure 2). Ultimate load per mm thickness
measurements demonstrated that electrospun chitosan membranes did experience a 48%
increase in tear strength with 10 mM genipin crosslinking which was not significant
(Figure 3). However, the strength exhibited by the chitosan membranes was less than the
commercially available glutaraldehyde-crosslinked collagen membranes. Even at the
higher 10 mM concentration of genipin, the ultimate load was 51% of the BioMend
Extend. Crystallinity measurements made by XRD showed that chitosan decreased in
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crystallinity with crosslinking by 15-17% (p=0.013) with no significant difference
between the 2 levels of crosslinking (Table 1). Molecular weight measurements revealed
that chitosan chain length is decrease upon electrospinning from 311 kDa to 77 kDa
(Table 2).
The fibroblast growth study indicated that cells were able to attach and proliferate
on the chitosan membranes (Figure 4). There were no differences detected between the
different levels of genipin crosslinking with respect to fibroblast growth.
Results from the TIB 71TM RAW 264.7 monocyte culture indicate that the
chitosan and collagen membranes are not pro-inflammatory. All NO levels from cells
seeded on membrane materials were lower than those on tissue culture plastic (Figure 5).
Additionally, in the presence of LPS, NO secretion by the monocyte cells was reduced by
the chitosan and collagen membranes (Figure 6). On day 1, the type I collagen
membranes reduced NO release by 97% and the chitosan membranes (un-cross-linked or
cross-linked) reduced NO release by 59-68%. On day 2, the type I collagen membranes
reduced NO release by 107% and the chitosan membranes (un-cross-linked or crosslinked) reduced NO release by 53-60%. On day 3, the type I collagen membranes
reduced NO release by 106% and the chitosan membranes reduced NO release by 5060%.

At the day 3 terminal timepoint, viability measurements made in a separate

experiment using Cell Titre GLOTM revealed that the viability of cells on glutaraldehydecrosslinked collagen was lower than control and cells growing on chitosan membranes
(Figure 7).
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Figure 1 – Suture pullout tests were conducted at 1 mm/min extension rate and
maximum load was recorded (n=4).

A

B

C

D

Figure 2 – Torn specimens after suture pullout for A) Collagen membrane
B) Electrospun chitosan membrane C) 5 mM genipin-crosslinked electrospun
chitosan and D) 10 mM genipin-crosslinked electrospun chitosan. Circles are drawn
to highlight the material tear. All specimens tore as expected towards the upper
edge.
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Figure 3 – Ultimate suture pullout load normalized to membrane thickness of the
electrospun membranes showed no significant increase in strength with
crosslinking. All test membranes tore at lower loads than commercially available
collagen membrane (n=4).

TABLE 1 – Crystallinity of the nanofibrous membranes ground intro coarse
powder and analyzed by XRD. Note that uncrosslinkied membranes exhibited the
largest crystalline peak at 2θ=20 (* indicates significance, p=0.013).
Groups
Uncrosslinked
5 mM genipin
10 mM genipin

Average CI (%)
37.0 (*)
20.9
23.1

Standard Deviation
6.1
3.0
8.9

TABLE 2 – Molecular weight (Mw) Molecular number (Mn) and polydispersity
index (PDI) of chitosan before and after electrospinning using TFA/DCM.
Starting material
Electrospun material

Mw
311,500
77,270

Mn
239,200
54,400
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PDI
1.30
1.42

100000
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Number of NhDF cells
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70000
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Chitosan Membrane
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5 mM Genipin

40000

10 mM genipin
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20000
10000
0
Day 1

Day 5

Day 9

Figure 4 – NhDF proliferation over nine days demonstrated cytocompatibility and
there was no significant difference between the groups (n=4).

8
7

NO production (uM)

6
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5

Chitosan (-)

4

5 mM Genipin (-)

3

10 mM genipin (-)

2

Collagen (-)

1
0
-1

Day 1

Day 2

Day 3

Figure 5 – NO production in the absence of LPS by RAW 264.7 cells seeded on
tissue culture plastic (control) test and commercially available GBR membranes
(collagen). In the absence of LPS, test materials did not stimulate NO production
compared to control.
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Figure 6 – NO production in LPS stimulated RAW 264.7 monocyte cells on tissue
culture plastic (control), test materials and commercially available GTR membrane.
Tissue culture plastic (control) produced significantly more NO than cells on
chitosan or collagen GTR membranes when stimulated with LPS (n=4). However,
the NO levels on measured from the glutaraldehyde-crosslinked collagen group may
have been low due to low cell viability. Dotted line shows baseline expression as
measured from unstimulated control cells (figure 5).
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1000000
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Figure 7 – Viability of RAW 264.7 monocyte cells measured at the day 3 terminal
timepoint. There was no effect with LPS treatment. Viability on glutaraldehydecrosslinked collagen membrane was significantly lower than other groups (a and b)
(p=3.8x10-13). Viability also appears low on uncrosslinked chitosan but this may
have been due to interference caused by membrane dissolution during the assay.
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DISCUSSION
Tensile testing in a previous study showed dose dependent improvement in tensile
strength with genipin-crosslinking [Norowski et al., in review]. However, in the suture
pullout test only a modest and insignificant increase from 9.3 to 13.8 N/mm in tear
ultimate load was observed with genipin crosslinking. One explanation as to why genipin
crosslinking benefited the tensile strength but did not benefit the tear strength is that these
are thin polymer membranes which are not resistant to tearing once a defect is
introduced. When the suture is placed, a tear is introduced in the membrane and the
small, non-woven, fibers do not offer substantial resistance to tear propagation. Further,
the tear strengths of the chitosan membranes were significantly less than that of the
BioMend Extend crosslinked collagen membranes tested. It should be noted that the
thickness of the BioMend Extend is significantly greater than the chitosan membrane
(0.39 vs 0.05 mm). BioMend Extend is designed to be thicker than other collagen
membranes for a longer duration of degradation: 18 weeks as opposed to 8 weeks for
BioMend (Zimmer product description). However, even when maximum load is
normalized to membrane thickness, the strength of electrospun chitosan membranes was
well below that of type 1 collagen. Increased suture pullout strength could possibly be
achieved by increasing fiber entanglement/adhesion of the membrane.
Results from the XRD suggest that genipin crosslinking reduces crystallinity by
disrupting chain packing of the chitosan. This is commonly seen for crosslinked polymer
materials. Results from the SEC-MALS indicate that the chitosan polymer is decreasing
in molecular weight during the electrospinning process. This reduction can be explained
by the solvents used to electrospin, which may cause chain scission. Unfortunately, the
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crosslinked membranes did not go into solution using various concentrations of acetic
acid, nor HCl, so measurements were not possible.

Reduced crystallinity and molecular

weight may have contributed to lower fiber mechanical properties which contributed to
the low tear strengths measured in this study.
The nine-day fibroblast growth study demonstrated that the chitosan membrane is
cytocompatible and will not inhibit fibroblast proliferation. The attachment and growth
of NhDF cells were unaffected by crosslinking degree. Sangsanoh et al., who evaluated
Schwann cell proliferation over a five-day period on uncrosslinked chitosan electrospun
mats, demonstrated a similar capacity for the chitosan nanofibrous mats to support cell
proliferation.27 These results are in agreement with our previous studies which showed
that genipin-crosslinked electrospun chitosan mats were not cytotoxic to SAOS-2
osteoblastic cells [Norowski et al., in review]. It was also reported that genipin
crosslinking of electrospun silk fibroin/hydroxybutyl chitosan resulted in cytocompatible
materials when tested for wound healing in rats and in vitro cytocompatibility.28 These
studies demonstrated the in vitro biocompatibility of the electrospun chitosan mats and
genipin-crosslinked electrospun chitosan mats.
The chitosan membranes in the RAW 264.7 monocyte study did not stimulate
cells to produce NO in the absence of LPS. Viability measurements revealed that
viability was not dependent on LPS stimulation, but that the glutaraldehyde crosslinked
collagen membrane did have lower viability than cells on chitosan membranes or tissue
culture plastic (p=3.8x10-13). The Biomend Extend collagen membrane also exhibited
low levels of NO production in the absence of LPS which may have been caused by low
cell viability. Bovine type I collagen has also been reported to interact with RAW 264.7
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monocyte cells by inhibiting or halting their proliferation and cell division.29 This was
noted in our study because of low viability in both unstimulated and LPS-stimulated cells
grown on BioMend Extend membranes. In addition, the media in the collagen membrane
groups did not change color to yellow due to metabolic activity like all other wells, but
instead stayed the initial red color. Bovine, but not rat or murine, type I collagen has also
been reported to stimulate NO production in RAW 264.7 cells30 and to modulate the
effects of other factors such as osteopontin in the presence of LPS stimulation.31 This
interaction of the murine cells on bovine collagen may have been responsible for the
decreased viability observed; however, glutaraldehyde crosslinking may have also
contributed to the low viability.
In LPS-stimulated groups, electrospun chitosan membranes reduced NO
production by RAW 264.7 cells. This effect has been reported in other studies using
chitosan oligosaccharide with RAW 264.7 and other inflammatory cell types.18-21,32
These studies have noted that the ability of chitosan to reduce NO production is
dependent on chitosan chain length, water-solubility, and also the nano-structure since
chitosan nanoparticles, and high molecular weight water-soluble chitosans were reported
to stimulate RAW 264.7 cells to produce NO at levels similar to positive control of LPS
or TNF-α.33-35 The ability of chitosan to inhibit monocyte activation has been attributed
to competitive binding of the surface receptor of the LPS ligand. Once chitosan has
bound the receptor, the MW, solubility, and nano-architecture play a role in whether the
receptor is activated or inactivated.18,19 In general, lower molecular weight chitosans are
reported inhibit NO production, while higher molecular weight and water soluble
chitosans stimulate monocytes to produce NO.35 In this study, electrospun chitosan mats
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have both a low Mw, around 73 kDa after electrospinning, and low solubility due to
neutralization and crosslinking processes, which may have contributed to its ability to
inhibit NO production. Genipin-crosslinked electrospun-chitosan membranes suppressed
LPS-induced monocyte-mediated NO production, without affecting cell viability or
proliferation. This reduction may be beneficial for patients suffering from periodontits,
an inflammatory disease which results in the destruction of teeth supporting bone and soft
tissue. This disease has been associated with elevated levels of NO in the gingival and
periodontal tissues.15-17 Therapies that inhibit NO production may therefore be
beneficial, and localized inhibition would be preferable to systemic inhibition, making
GTR materials a good candidate for the localized suppression of host-mediated NO
signaling.
Modulation of the host response has been proposed as a therapeutic approach for
halting tissue destruction associated with periodontitis.14 Monocytes, when activated, can
further differentiate into macrophages, pre-osteoclasts, and osteoclasts, the cells primarily
responsible for inflammatory tissue destruction. A GTR membrane that inhibits NO
production and reduces monocyte activation may benefit patients with chronic
periodontitis undergoing GBR procedures. From our in vitro evaluations, improvements
are still needed in the tear strength of chtiosan membranes before robust clinical
applications. Continued efforts are underway to improve the strength and thickness of
electrospun chitosan membranes as well as investigating drug loading/release studies to
evaluate the potential of electrospun chitosan membranes to act as carrier material for
antibiotics and/or growth factors around the graft site.
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CONCLUSION
XRD measurements revealed that crystallinity is decrease upon crosslinking with
genipin. In vitro biocompatibility testing demonstrated that genipin crosslinking did not
have an inhibitory effect on the proliferation of fibroblasts. Electrospun chitosan and
genipin-crosslinked electrospun chitosan did not activate RAW 264.7 cells in the absence
of LPS. In the presence of LPS, electrospun chitosan and genipin-crosslinked
electrospun chitosan mats decreased LPS-induced NO expression in RAW 264.7
monocyte cells. Electrospun chitosan materials demonstrated lower suture pullout
strengths than commercially available collagen membranes, even when crosslinked with
genipin, demonstrating that improvements are still needed to increase the tear strength
before they can successfully be applied as GTR barrier membranes.
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CHAPTER 4: Submission to the Journal of Antimicrobial Chemotherapy
Antimicrobial activity of minocycline-loaded genipin-crosslinked nano-fibrous
chitosan mats for guided tissue regeneration.
Authors: Norowski, PA, Babu, J, Adatrow, PC, Haggard, WO, Bumgardner, JD.

Abstract
Antimicrobial delivery has been advocated for guided tissue regeneration (GTR) or
guided bone regeneration (GBR) therapies involving patients with aggressive or
unresolved periodontitis/peri-implantitis. Electrospun chitosan membranes demonstrate
several advantages over traditional GTR barrier membranes because they stimulate
healing, mimic the topology of the extracellular matrix, and allow for diffusion of
nutrients and wastes into/out of the graft site, and were shown to stimulate bone
formation in a rabbit calvarial critical-size defect model. Previously, we have shown
improvements in mechanical properties and degradation kinetics by crosslinking
electrospun membranes with 5 mM or 10 mM genipin. We have also previously
demonstrated the ability of elecrospun chitosan membranes to inhibit lippopolysaccharide
(LPS)-induced monocyte activation. In this study, minocycline was incorporated into the
chitosan membrane by passive absorption at 5 or 10 mg/mL. The minocycline-loaded
membranes and control membranes (carrier only) were tested against Porphyromonas
gingivalis (P. gingivalis) by repeated zone of inhibition measurements. Results show that
uncrosslinked and genipin-crosslinked membranes have similar capacity to absorb
aqueous solutions. Minocycline loading resulted in bacterial inhibition for up to 8 days
from crosslinked membranes whereas uncrosslinked membranes loaded with minocycline
only inhibited bacteria for 4 days. These in vitro results suggest that genipin-crosslinked
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electrospun chitosan membranes loaded with minocycline may be able to reduce early
bacterial contamination of GTR graft sites.
Introduction
Electrospun chitosan and other chitosan membrane materials have been advocated
for guided bone regeneration (GBR) and guided tissue regeneration (GTR) barrier
membranes.1-3 Electrospun material are advantageous because they mimic the topology
of the extracellular matrix4, allow the diffusion of nutrients and waste, while having a
small enough pore size to limit cellular infiltration. Electrospun materials also have the
capability to regenerate dense cortical bone in animal models.5
Chitosan is advantageous because it has been reported to stimulate the healing of
dental pulp wounds,6 is osteogenic,7 and has been shown to inhibit lippopolysaccharide
(LPS)-induced monocyte activation.8-11 However, improvements are needed in the
clinical handle-ability, strength, and degradation timeframe of electrospun chitosan for
clinical GTR applications. We have shown previously that crosslinking electrospun
chitosan membranes with genipin resulted in 12% reduction in mass loss over 16 weeks,
and increased the tensile strength of the membranes three fold [Norowski et al., in
review]. We have also demonstrated that the genipin crosslinked chitosan membranes
were not cytotoxic to osteoblast or fibroblast cells, and did not cause monocyte
activation. Electrospun chitosan material may have the capacity to deliver
antimicrobials, such as minocycline, during GTR regeneration of periodontal lesions in a
manner similar to Arestin® (OraPharma, Warminster PA, USA) which is used for the
extended local delivery of minocycline to periodontal pockets.12 This product consists of

55

microencapsulated minocycline in which the microcapsules are composed of PLGA
synthetic co-polymer.
Periodontitis is an inflammatory disease that is driven by the presence of gramnegative periopathogens in the gingival tissues. These pathogens secrete LPS, a potent
inflammatory molecule, which drives host inflammatory response. Monocytes, activated
macrophages and polymorphonuclear leukocytes (PMNs) respond to secreted LPS by
participating in paracrine and autocrine signaling amplification using NO, IL-1β and
TNF-α among a myriad of other cytokines.13 Ultimately these signaling cascades lead to
the recruitment of cells that release tissue destroying enzymes, namely collagenase,
MMP-2, MMP-8, MMP-9 among others. Therapeutics that have the ability to inhibit
MMPs or inflammatory cell activation may potentially limit tissue and bone destruction
associated with periodontitis and other inflammatory diseases.14 Previously, we have
shown the ability of genipin crosslinked electropun chitosan membranes to inhibit the
LPS-induced release of NO from RAW 264.7 monocyte cells over a 3 day period
[Norowski, in review]. NO expression is elevated in the periodontal and gingival tissues
of patients with periodontitis and its inhibition is a potential therapeutic target.15-17
Minocycline is commonly used in periodontal therapy as an antimicrobial agent but it
also has the ability to limit tissue destruction, by inhibition of tissue destroying enzymes
such as collagenase, MMP-2 and MMP-9.18
In this study, uncrosslinked and genipin crosslinked electrospun chitosan
membranes were impregnated by immersion in 10 mg/mL minocycline or 5 mg/mL
minocycline and tested against Porphyromonas gingivalis (P. gingivalis) by zone of
inhibition. P. gingivalis is an important and extensively studied periodontal pathogen
56

involved in the pathogenesis of periodontitis. In addition, swelling was measured to
assess the capacity of the electrospun membranes to absorb aqueous solutions.

57

Materials and Methods
Electrospinning procedure
Electrospun chitosan nanofibrous mats were fabricated as previously described
[Norowski et al., in review]. Briefly, a 5.50wt% chitosan solution in 70(v/v)%
trifluoroacetic acid and 30(v/v)% methylene chloride was mixed with genipin for 30
minutes prior to the start of electrospinning. The genipin concentrations investigated
were 0, 5, or 10 mM. The solution was electrospun at 25 kV and the fibers were
collected on a non-stick aluminum foil target, rotated at 8.4 RPM by an AC motor to
ensure even and random distribution of fibers. After electrospinning, the nano-fibrous
mat was put under vacuum overnight to remove residual solvent, removed from the foil,
and then neutralized at room temperature in 5M Na 2 CO 3 (saturated solution) for 3
hours.19 Membranes were sterilized by ethylene oxide gas.
Swelling
The swelling index of the nanofibrous membranes was determined by a swelling test.
Swelling in phosphate buffered saline (PBS) was evaluated to estimate the amount of
antibiotic solution that could be absorbed by the electrospun membranes. To determine
the dry weight, membranes were maintained at 40 oC overnight in a drying oven. After
measuring the dry weight, membranes were submerged in PBS for 1 hr (±15 minutes) to
ensure complete swelling. Swelling index was calculated by (Wt WET - Wt DRY )/Wt DRY .
Minocycline loading
Minocycline was loaded into chitosan nano-fibrous membranes by passive absorption.
Pre-cut, pre-sterilized circular specimens (10 mm diameter), were submersed in
minocycline solution (10 or 5 mg/mL in de-ionized water) for 15 minutes. Negative
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controls were submersed in de-ionized water only.

Minocycline solutions were weighed

before and after membrane swelling to determine the amount of antibiotic solution
absorbed.
P. gingivalis Zone of Inhibition (ZOI)
The model periodontal pathogen used in this study was Porphyromonas gingivalis
(ATCC No 33277) which was originally isolated from human gingival sulcus. Bacteria
were maintained as frozen stock cultures and grown anaerobically at 37oC in trypticase
soy broth (BD BBL, Franklin Lakes, NJ, USA) supplemented with 1 g of yeast extract
per liter, 5 mg of hemin per liter, and 1 mg of menadione per liter. After 72 hours of
growth, bacteria were collected and resuspended to contain 1x107 cells/ml. A suspension
(0.5 ml) of this stock suspension was spread on a blood agar plate (BD BBL, Franklin
Lakes, NJ, USA) and the electrospun chitosan mats loaded with minocycline were placed
onto the agar and incubated in an anaerobic jar with an anaerobic pack. Plates were
checked for ZOI by serially placing membranes on freshly seeded bacterial lawns and
recording ZOI at days 1, 4, 6, 8 and 11 (n=2).
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Results
Swelling experiments demonstrated that the electrospun membranes have a swelling ratio
around 2.0 (Figure 1). The amount of swelling that occurred was not significantly
affected by crosslinking (p=0.29). Although swelling was allowed to occur for 1 hour to
ensure complete swelling, the membranes appeared to be fully hydrated within 5 minutes
(data not shown). Submersion in 10 mg/mL minocycline solution resulted in 0.52, 0.53,
and 0.38 mg of minocycline uptake for uncrosslinked, 5 mM crosslinked and 10 mM
genipin-crosslinked membranes, respectively.
Bacterial ZOI testing demonstrated extended release of minocycline from the
barrier membrane in vitro for up to 8 days after soaking in 10 mg/mL (figure 2) or 5
mg/mL (figure 3) minocycline for 15 minutes. It was noted that uncrosslinked
membranes only remained bacteriostatic for 4 days as opposed to both levels of
crosslinking which remained bacteriostatic for 8 days. None of the negative controls
(carrier only) produced zones of inhibition.
3

Swelling ratio

2.5
2
1.5
1
0.5
0
Uncrosslinked
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10 mM

Figure 1 – Swelling ratio of the nanofibrous chitosan mats. There were no
significant differences between groups (p=0.29, n=4,*n=5 in 5 mM group)
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Figure 2 – Inhibition of P. gingivalis over an 11 day period by electrospun chitosan
membrane loaded with 10 mg/mL minocycline. Error bars represent the spread of
measurements (n=2).
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Figure 3 – Inhibition of P. gingivalis over an 11 day period by electrospun chitosan
membrane loaded with 5 mg/mL minocycline. Error bars represent the spread of
measurements (n=2).
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Discussion
The slightly reduced swelling experience by crosslinked membranes may have
been caused by decreased chain packing and restricted chain movement. Since the
membranes absorb comparable amounts of fluid and the slight reduction in swelling was
not significant, the crosslinked membrane should have similar capacity to absorb drugs,
antibiotics, or growth factor solutions. Unlike vapor crosslinking and solution
crosslinking, where materials are exposed to a crosslinking agent which crosslinks the
surface of the material only, in this study, the crosslinking agent is dispersed within the
polymer solution used for scaffold fabrication. This situation creates a more uniformly
and thoroughly crosslinked membrane, which may contribute to antibiotic retention and
more uniform degradation kinetics. A previous examination using x-ray diffraction
showed that crystallinity was decreased during crosslinking. This may have contributed
to slightly lower swelling volumes, however this difference was not significant, and the
amount of minocycline loaded into the membranes was comparable.
In this study, genipin-crosslinked electrospun chitosan was able to absorb
minocycline and release it in an extended manner that remained bacteriostatic for longer
periods than uncrosslinked membranes (8 days as compared to 4 days). These results are
similar to reports by others who have loaded biodegradable GTR membranes with
antibiotics/antiseptics such as tetracycline, doxycycline or chlorhexidine.20-22 The
delayed degradation kinetics [Norowski et al., in review] contributed to the extended
release seen from crosslinked membranes. Thus, uncrosslinked chitosan membranes
degraded faster, and resulted in a faster burst release of minocycline.
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One clinical investigation reported no improvements in clinical parameters
associated with the local application of minocycline ointment before GTR therapy, but
this study did not investigate minocycline incorporation into the GTR membrane itself,
and only investigated the use of type 1 collagen membranes.23 Other investigations with
a non-membrane local delivery system demonstrated improvement in clinical parameters
associated with the use of minocycline microcapsules (Arestin®).12 This microcapsule
study also showed that reduction in periodontal pocket probing depth (improved clinical
outcomes) correlated strongly with the ability to inhibit red complex bacteria in vitro, a
sub-group of periodontal pathogens that includes P. gingivalis, T. forsythia, and T.
denticola.12 This correlation strongly suggests that minocycline-loaded genipincrosslinked electrospun chitosan mats could be beneficial to patients with unresolved
periodontitis undergoing GTR surgery, since they inhibited P. gingivalis, a red-complex
bacteria, in vitro.
Conclusion
In this study, we have shown the ability of genipin-crosslinked electrospun
chitosan to deliver clinically relevant levels of minocycline over an 8 day period. The
eluted minocycline was able to inhibit growth of P. gingivalis, a model periopathogen, in
vitro. Crosslinked membranes released inhibitory concentrations of minocycline for 8
days while, uncrosslinked membranes only inhibited growth for 4 days. This prolonged
minocycline elution profile suggests that genipin-crosslinking improved the drug-carrier
properties of electrospun chitosan.
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Chapter 5. Conclusions
In this study, the design criteria for the chitosan based GTR membrane was to be able to
exclude the soft tissue (i.e. cell occlusive), to degrade on a time scale consistent with
healing and osseous tissue maturation, to provide a topology and nanostructure that
supports cell attachment/tissue integration, to provide bioactivity by stimulating wound
healing and osseous regeneration through the inherent properties of chitosan, or through
the delivery of some bioactive compound. To meet the design criteria, three GTR barrier
membranes formulations were fabricated from chitosan by electrospinning, and
chemically modified by incorporation of genipin at 5 mM or 10 mM concentrations
during the electrospinning process. These electrospun chitosan membranes and
crosslinked membranes were evaluated in vitro for their capacity to perform as a GTR
barrier membrane. Chitosan membranes were evaluated to act as carriers for local
delivery of the periodontal antibiotic, minocycline. Minocycline is also beneficial to
patients with periodontitis because it is a collagenase and MMP inhibitor [65, 66], thus
limiting tissue destruction and gingival recession associated with periodontitis.
Results from the XRD, FTIR, as well as physical changes in, color, rigidity, are
evidence that chemical crosslinking occurred during genipin incorporation. Specifically,
results from FTIR analysis showed a dose dependent reduction in the amount of free
amino groups, indicating that genipin was binding the amino groups during crosslinking.
We also demonstrated by SEM imaging that the mean fiber diameter was not
significantly affected by crosslinking. Additionally, altered in vitro biodegradation was
observed, with crosslinking causing a 12% delay in mass loss over a 16 week period.
However, the bioactive properties and biocompatibility of the membranes was not
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affected by genipin-crosslinking in cultures of osteoblasts, fibroblasts, and monocyte
cells. Tensile strength was also significantly increased by 265% with 10 mM genipin
crosslinking, but suture pullout strength was increased by only 44% which was not
significant. Increases in mechanical strength appeared to be genipin-dose dependent.
These results suggest that genipin-crosslinking benefits the tensile properties and
improves the handling characteristics of the membranes, but does not particularly benefit
the tear strength of the membrane which is more indicative of clinical performance when
the membrane is sutured. The tear strength of electrospun chitosan membranes must be
improved for clinical application, because it was significantly lower than that of
BioMend Extend (Zimmer Dental, Carlsbad, CA). This improvement could be achieved
by increasing the thickness of the electrospun mats, or by increasing fiber
entanglement/adhesion and/or decreasing the amount of bead defects.
XRD showed that electrospun membranes were more crystalline without
crosslinking. The reduction in crystallinity was from 37 % crystallinity index, to 20 %
crystallinity index, which was statistically significant. Importantly, the reduction in
crystallinity did not significantly affect the swelling capabilities of the crosslinked
membrane. Swelling tests of the membranes demonstrated little or no difference in saline
uptake with crosslinking, indicating that crosslinked membranes could be loaded with
antimicrobials or growth factors in a manner similar to uncrosslinked membranes.
When submersed in a solution of 10 or 5 mg/mL minocycline the genipin-crosslinked
membranes provided an extended antimicrobial action against model periodontal
pathogen P. gingivalis for up to 8 days as compared to only 4 days for uncrosslinked.
This duration of antimicrobial action should be sufficient to allow primary soft tissue
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healing and attachment in the absence of periodontal pathogens. Furthermore,
minocycline also has the ability to inhibit collagenase and certain MMPs [27, 65, 66],
indicating that minocycline loaded chitosan membranes could potentially provide
extended bone and soft tissue-sparing bioactivities.
The results of this investigation have shown that genipin-crosslinked electrospun
chitosan mats have beneficial biological properties including cytocompatibility, the
ability to inhibit LPS-induced monocyte activation, and the ability to deliver minocycline
over an 8 day period which offers clinical advantage over current collagen membranes.
However, improvements in the shear strength and clinical handle-ability of electrospun
chitosan mats are still needed.
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Chapter 6. Recommendations
The genipin-crosslinked electrospun chitosan mats are a promising material for
GTR barrier membrane implants. These in vitro investigations on the genipincrosslinked electrospun chitosan have shown that improvements are needed in the tear
strength of the material. One approach for a more rapid development would be to not
develop electrospun chitosan as a stand-alone GTR membrane, which would require the
engineering of electrospun materials to obtain optimal mechanical strength and
degradation kinetics. Instead, the application of electrospinning technology to already
clinically-used collagen membranes would result in a bi-layer composite construct. The
bi-layer construct can easily be accomplished by directly electrospinning chitosan onto a
collagen membrane substrate. This approach would result in a bioactive surface, which
could promote cell attachment and reduce LPS-induced monocyte activation but would
also have the beneficial handling properties of collagen membranes that clinicians prefer
and are familiar with.
Another recommendation is to increase the thickness of the resultant membrane to
increase mechanical properties and improve handling characteristics of the membrane.
This could be accomplished by increasing the efficiency of the elecrospinning process, by
allowing less material to be lost during the spinning process. It could also be
accomplished by decreasing the target size, which would result in a smaller, but thicker,
membrane.
Investigations into the in vivo general biocompatibility are necessary to confirm
tissue compatibility and in vivo degradation timeframe. A good model for this would be
the Sprague-Dawley rat intramuscular pouch model. The next logical step, after
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demonstrating basic tissue compatibility, would be to use a pre-clinical animal model to
evaluate under conditions of intended use the potential of minocycline-loaded genipincrosslinked electrospun chitosan membranes to inhibit chronic periodontitis. One
possible model is the LPS-induced osteolysis model of aggressive periodontitis used to
evaluate potential bone sparing therapies [44]. In this model, Sprague-Dawley rats are
given palatal molar gingival injections of LPS derived from Actinobaccilus
actinomycetemcomitans three times per week for 8 weeks. At 8 weeks, alveolar bone
loss is measured by µCT [44]. This would represent a worst-case scenario and would be
a challenging model to establish efficacy of minocycline-loaded genipin-crosslinked
electrospun chitosan membranes to inhibit/reduce tissue destruction associated with
aggressive/chronic periodontitis. However, this animal model does not fully capture the
etiology and pathogenesis of periodontitis, because it doesn’t cause bone loss from
pathogenic dental plaque but from direct injection of LPS into the gingival tissues.
The most appropriate (and more expensive) animal model for periodontitis would
be ligature-induced bone loss model in non-human primates [67]. In this model, bony
defects are created around teeth using wire ligatures are positioned to extend from the
oral cavity into the defect space. This model allows for plaque accumulation on the wire
ligature and results in chronic inflammation, leading to bone loss. After a bone loss has
occurred, the ligatures are removed and experimental materials can be applied. Often a
small notch is placed in the root of the tooth to mark the original defect depth, and so that
measurements can later be obtained. Histological measurements are taken to examine the
height of regeneration which has occurred from the base of the tooth notch to the most
coronal extension of bone, periodontal ligament, and cementum tissues [67]. This pre-
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clinical model most closely approximates the clinical manifestations of periodontitis in
humans, and would be the best method to evaluate potential therapies.
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